C12N 2800/206
Of yeast origin
Official title: of yeast origin, e.g. YAC, 2u
C12N2800/206 (Of yeast origin) appears on 52 US grants and 60 published applications in this corpus.
Search patents in C12N- Granted patents
- 52
- Published applications
- 60
- Assignees
- 42
- Inventors
- 115
- Latest grant
- 10 Jan 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 6 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 1 |
| 2002 | 1 | 9 |
| 2003 | 3 | 7 |
| 2004 | 4 | 7 |
| 2005 | 2 | 2 |
| 2006 | 2 | 6 |
| 2007 | 1 | 2 |
| 2008 | 1 | 5 |
| 2009 | 1 | 5 |
| 2010 | 1 | 2 |
| 2011 | 1 | 1 |
| 2012 | 2 | 0 |
| 2013 | 2 | 2 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 2 | 1 |
| 2017 | 1 | 2 |
| 2018 | 1 | 3 |
| 2019 | 1 | 2 |
| 2020 | 2 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Transgenic mice10 Jan 2023US 11,547,099 B2Crescendo Biologies Limited
- Ungulates with genetically modified immune systems10 Aug 2021US 11,085,054 B2Revivicor, Inc.
- Triple-mode system for antibody maturation, surface display and secretion7 Jul 2020US 10,704,040 B2Abzyme Therapeutics LLC
- Modulation of BCL11A for treatment of hemoglobinopathies25 Feb 2020US 10,570,392 B2Children's Medical Center Corporation
- Modulation of BCL11A for treatment of hemoglobinopathies23 Apr 2019US 10,266,826 B2Children's Medical Center Corporation
- Transgenic mice4 May 2023US 2023/0133028 A1Crescendo Biologics Limited
- Ungulates with Genetically Modified Immune Systems9 Apr 2020US 2020/0109415 A1Revivicor, Inc.
- Novel saccharomyces cerevisiae expression system and construction method thereof25 Jul 2019US 2019/0225973 A1Qilu University of Technology
- Modulation of bcl11a for treatment of hemoglobinopathies6 Jun 2019US 2019/0169615 A1Children's Medical Center Corporation
- Transgenic mice20 Dec 2018US 2018/0362666 A1Crescendo Biologics Limited
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Transgenic non-human animals for producing heterologous antibodies679US 5,814,318 AGenPharm International, Inc. · 1998